A prognostic model based on seven genes associated with sorafenib resistance—ANAPC13, NCAPD2, KIF2C, CDK5RAP2, MANBA, PPAT, and LPCAT1—offers a promising foundation for personalized treatment of HCC patients and may enhance the accuracy of prognostic assessments. The gene discussed is LPCAT1; the disease is hepatocellular carcinoma.